Merck and Wyeth weren't the only ones. The Associated Press reports that GlaxoSmithKline had a ghostwriting program to support its antidepressant, Paxil. The program, called CASSPER, instructed salespeople to approach physicians and help them write and publish positive articles about the antidepressant. Los Angeles law firm Baum Hedlund is suing GSK and says they downplayed the risks of the drug. GSK says the program was discontinued many years ago.
A Friendly Ghostwritten Paper for Paxil
Aug 21, 2009